ATAI News and Press, ATAI Life Sciences N.V. From 01/26/24

Researchers from the University of Split’s Medical School’s Department of Medical Humanities recently used computerized linguistic tools to gain insight into online reports of mystical psychedelic experiences. The scientists found that intense psychedelic experiences tend to be ...

2024-01-24 09:00:41 ET Palm Beach, FL – January 24, 2024 – FN Media Group News Commentary – The coming years could see a massive shift in the U.S. government’s approach to regulating hallucinogenic drugs. Several biopharma companies are developing psy...

A recent study has suggested that psychedelics may deliver their antidepressive effects by “shaking up” the brain networks responsible for regulating emotion. Major advances in psychedelic research have revealed that classic psychedelics have the potential to treat various mental...

2024-01-09 13:56:16 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Though psychedelic therapies and related psychedelic stocks have fallen out of favor recently, there’s still tremendous research and insight happening beneath the surface. Even Elon Mu...

2024-01-09 12:00:00 ET Summary Critical catalysts are approaching in the psychedelic sector, with the potential for the first FDA-approved psychedelic therapy by the end of the year. Alex Carchidi shares why Compass Pathways, Cybin, and Atai are the most promising companies for in...

2024-01-09 08:35:20 ET BT Brands  ( BTBD ) +135% . Sentage Holdings ( SNTG ) +95% . Juniper Networks  ( JNPR ) +23% jumps 25% on report HPE is nearing buyout deal. Syra Health  ( SYRA ) +17% . Elicio Therapeutics  ( ELT...

2024-01-04 15:05:54 ET More on ATAI Life Sciences Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value Atai Life Sciences climbs on Phase 1 data for ecstasy candidate Seeking Alpha’s Quant Rating on ATAI Life Scien...

Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidates Two patent-protected, clinical-stage programs BPL-003 (intranasal 5-MeO-DMT) and ELE-101 (intrave...

2024-01-02 15:43:22 ET More on ATAI Life Sciences Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value Seeking Alpha’s Quant Rating on ATAI Life Sciences Historical earnings data for ATAI Life Sciences Fina...

EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expected The PK profile of EMP-01 was dose-proportional, and a range of exploratory pharmacodynamic (PD) measures, including subjective reports and blood-based biomarkers, showed dose-depende...